During August, the number of short positions, also known as contracts for difference, that was held on shares of Health Catalyst, Inc. declined by a sizeable amount (NASDAQ: HCAT). Compared to the 3,730,000 shares that were borrowed the day before, the number of shares that were borrowed on August 15 was 3,170,000, reflecting a drop of 15.0% from the previous day’s total.
This statistic is derived from the fact that the stock’s typical trading volume is 1,120,000 shares, and it is now expressed as a ratio that is referred to as the short-interest ratio. Based on this data, there are currently 2.8 times more short positions than long ones in the market. Wall Street experts have published recommendations of the top 10 stocks they believe investors should hold in June of 2021. These analysts feel that investors should buy these stocks because they are expected to perform well. On August 18, Director Duncan Gallagher purchased 8,400 shares of the company’s stock.
This piece of news is significant to this topic and is related to it. This information was presented in the paragraph before this one. The price of each share was 11.69 dollars, resulting in the total amount spent on the acquisition being 98.196 dollars. The price that was paid for each share was 11.69 dollars. As a result of the transaction being completed, the director is now the direct owner of 28,805 company shares, which have a combined market value of about $336,730.45. The Securities and Exchange Commission notified the transaction in the form of a filing submitted to the agency.
If you follow the link, you can view the whole filing that has been submitted. On June 6, the day after the market opened for trading, the general counsel for the company, Daniel H. Orenstein, sold 2,838 shares of the company’s stock. When divided by the total number of shares sold, the total price of $42,144.30 comes out to $14.85 for each share sold. The shares were sold on the open market. The general counsel currently owns 103,671 shares of the company’s stock, and the total value of those shares is around $1,539.514. If you click on this link, you will be led to a file that was just submitted to the SEC, giving you more information about the transaction you are interested in.
On August 18, director Duncan Gallagher purchased 8,400 shares of the company’s stock. The transaction took place on Thursday. In addition, Gallagher bought these shares of company stock. The price of each share was 11.69 dollars, resulting in the total amount spent on the acquisition being 98.196 dollars. The price that was paid for each share was 11.69 dollars. As a direct result of the successful transaction completion, the director is now the owner of 28,805 business shares, which have a total value of $336,730.45 in the current market. If you seek the relevant disclosure to this transaction, you need to look in this location.
During the most recent period of financial activity, corporate insiders were responsible for the sale of a total of 5,063 shares of stock, which resulted in a profit of $73,136. These shares were put up for sale during the most recent accounting period and eventually sold. The current management of the corporation and its workers own a combined total of 1.50 percent of the total number of shares that are accessible at the moment.
Hedge funds have been quite active in the stock market, continuously buying and selling shares in both directions. Brand new investment in Health Catalyst was made by Fairfield Bush & Co. during the first three months of this year. The total value of this investment was around $25,000 in its entirety. Macquarie Group Ltd. invested $26,000 in Health Catalyst during the second quarter. The value of this investment can be found in the phrase. During the last three months of 2018, UMB Bank, National Association of Missouri, made a further investment in the company Health Catalyst that was thirty thousand dollars more than their previous investment.
The value of Manchester Capital Management LLC’s holdings in Health Catalyst increased by a whopping 667.5% during the first three months of 2018. After acquiring an additional 1,008 shares of the company’s stock, Manchester Capital Management LLC now holds 1,159 shares. The value of all of Manchester Capital Management LLC’s company stock shares is $30,000. As a direct consequence of this development, the total number of shares in the corporation they own has increased to 30,088. Point72 Hong Kong Ltd., not to be outdone, added a new holding in Health Catalyst during the first quarter, which is believed to be worth approximately $33,000. It was done to compete with other companies.
This action was taken to compete with those taken by other businesses. Most of the company’s shareholders are comprised of institutional investors and hedge funds, as these entities hold a total of 96.58% of the company’s total number of shares. Recently, numerous brokerage firms from a wide range of different backgrounds have provided their feedback on HCAT. JPMorgan Chase & Co. downgraded Health Catalyst from “overweight” to “neutral” research published on Friday, August 5. Additionally, they dropped their target price from $20.00 to $16.00. BTIG Research produced a research note on July 27, in which they disclosed that they had decreased their price goal for Health Catalyst from $35.00 to $25.00. The announcement was made on July 27.
This piece of correspondence was labeled “Health Catalyst Price Target.” In a research report published on Friday, August 5, Stifel Nicolaus dropped its price target for Health Catalyst from $27.00 to $16.00 and downgraded the company from a “buy” rating to a “hold” rating in a research report. In addition, the firm downgraded its rating for the business from “hold” to “buy.” In addition, the company’s stock was lowered in a research report released on August 5 by the company. In a research report on May 11, Piper Sandler stated their intention to cut its price target for Health Catalyst from $38.00 to $21.00. As mentioned in a research note released on Wednesday, May 11, Citigroup has decreased its price objective for Health Catalyst from $45.00 to $25.00.
This information was provided. Two analysts have indicated that investors keep the same amount of stock in the firm they already own; nine analysts have recommended that investors buy company shares, and a single analyst has recommended that investors purchase the stock at an even higher price. According to the data provided by Bloomberg, the overall consensus price goal for the business is set at $26.69, and the current average rating for Health Catalyst is “Moderate Buy.” Tuesday was the first-day trading available for the NASDAQ: HCAT shares, and the opening price was $11.83. Throughout the last year and a half, the price of a single bottle of Health Catalyst has ranged from as low as $10.95 to as high as $57.19 at various times.
The simple moving average for the last 50 days of the company’s stock price is currently sitting at $14.80, and the simple moving average for the past 200 days is currently sitting at $18.51. In conjunction with Health Catalyst, healthcare companies can now purchase data, analytics tools, and services from Health Catalyst, Inc.
Its products include a commercial-grade data and analytics platform for the healthcare industry; artificial intelligence and data science, which combines AI with current business intelligence tools to increase the accuracy of analytics; population health management, which identifies improvements throughout the care continuum and offers actionable advice for success and automated workflows; and financial transformation, which offers insights into costs as well as labor.
All of these products are designed to improve patient’s quality of care. These goods are all developed to enhance the standard of care provided. In addition, it manages population health, which seeks methods to improve care in general and automates workflows.
